In the grand halls of India’s highest tribunal, the stark realities of pharmaceutical economics rarely arrive wrapped in delicate prose. When a bench composed of Justices Vikram Nath and Sandeep Mehta examined the pricing structures of life-saving cancer therapies, the judicial language lost its customary restraint. Confronted with evidence that a critical oncology drug costing a manufacturer roughly 2,700 rupees to supply was tagged with a Maximum Retail Price of 27,000 rupees, the court termed the practice daylight robbery.
The ten-fold markup is not an isolated anomaly. It is a symptom of a systemic policy failure in India’s health economy. While the country prides itself on being the pharmacy of the developing world, exporting billions of dollars worth of affordable generic medicines globally, its domestic market operates under a paradoxical structure. Tens of millions of citizens face catastrophic out-of-pocket medical expenditure, driven not by the actual cost of synthesizing molecules, but by administrative blind spots, institutional distortion, and flawed regulatory frameworks.
The Illusion of Control
To understand how a 900 percent markup thrives, one must examine India’s regulatory architecture. The central mechanism for controlling medicine costs is the Drugs Prices Control Order, administered by the National Pharmaceutical Pricing Authority. The framework relies heavily on the National List of Essential Medicines. When a drug molecule is placed on this scheduled list, its ceiling price is strictly capped based on the simple average of market-leading brands.
Yet this regulatory net is strikingly porous. Out of the roughly 60,000 active pharmaceutical formulations and branded generics traded across the country, only a fraction fall under direct price regulation. The vast majority operate as non-scheduled drugs, where manufacturers are permitted to increase prices by up to ten percent annually.
More critically, the regulatory architecture focuses heavily on standard essential formulations, leaving vast categories of life-saving treatments unregulated.
The Anatomy of Market Failure
In classical economics, competition among thousands of generic drug producers should drive prices down toward production cost. India boasts thousands of pharmaceutical manufacturing units, ensuring an abundance of supply. Yet market forces break down entirely in the healthcare sector due to a fundamental structural anomaly: demand is principal-agent driven.
Patients do not select their own prescription drugs; doctors and hospital procurement boards do so on their behalf. In an environment where the consumer lacks both the expertise and the structural power to choose alternatives, brand power and channel incentives dictate market share.
This dynamic creates perverse incentives for manufacturers. To secure placement in major hospital networks and corporate healthcare chains, drug makers often inflate the maximum retail price printed on the box. A higher retail price allows manufacturers to offer massive institutional discounts to hospitals and retail pharmacies. The hospital purchases the cancer drug at 2,700 rupees, bills the bedridden patient at 27,000 rupees, and pockets the difference to boost profit margins. The patient, facing a life-or-death diagnosis, has neither the leverage nor the time to shop around for a cheaper generic substitute.
Furthermore, pharmaceutical companies frequently evade ceiling prices by introducing minor reformulations. By combining standard molecules into fixed-dose combinations, a drug can be re-registered as a new non-scheduled formulation, escaping existing ceiling prices while offering no meaningful therapeutic superiority.
Public Insurance and Fiscal Leakage
The human toll of this market failure is immense, but the fiscal consequences for the state are equally severe. Over recent years, public healthcare insurance programs have expanded with the goal of protecting vulnerable households from medical bankruptcy. Under these schemes, the government reimburses hospitals and providers for inpatient care and expensive therapies.
When public health schemes purchase or reimburse medicines at inflated prices, taxpayer funds are effectively funneled directly into institutional markups. Rather than expanding healthcare access to a broader demographic, public expenditure is consumed by artificial price inflation. The state finds itself funding the very inefficiencies its regulatory agencies failed to curb.
Reclaiming the Prescription
Fixing India’s broken drug economy requires moving beyond piecemeal price freezes and tackling structural distortions at their root cause.
First, the distinction between scheduled and non-scheduled drugs requires urgent reform. Rather than maintaining a narrow list of essential medicines while leaving tens of thousands of formulations uncontrolled, regulators must establish capped trade margins across the entire supply chain. Limiting the maximum permissible spread between the ex-factory price and the final retail price would immediately eliminate the incentive for artificial price inflation.
Second, the government must address the crisis of confidence surrounding generic alternatives. Initiatives offering unbranded generic medicines at a fraction of retail prices provide a viable alternative in theory. However, adoption remains hindered by lingering doubts among physicians and patients regarding quality assurance and bioequivalence. Strengthening regulatory oversight and enforcing strict quality audits would give practitioners the confidence to prescribe affordable generics without reservation.
Finally, public procurement mechanisms must be modernized. State governments and central health agencies should leverage pooled procurement models, purchasing critical oncology and rare-disease medications directly from manufacturers in bulk to bypass intermediaries entirely.
The Supreme Court’s sharp intervention serves as a timely reminder that affordable healthcare is an essential component of economic stability. Leaving the pricing of life-saving therapeutics to distorted market incentives undermines public trust and weakens the broader health system. Until regulators align market incentives with patient welfare, equitable healthcare will remain out of reach for millions.